InMed Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
IMLFF InMed Pharmaceuticals Inc
PNW Pinnacle West Capital Corp
AAPL Apple Inc
NAII Natural Alternatives International Inc
SJMiv.P Invesco BulletShares 2022 Hi Yld Corp Bd ETF
INTC Intel Corp
VAL Valaris PLC
GE General Electric Co
XOM Exxon Mobil Corp
MSFT Microsoft Corp
Go

Health Care : Biotechnology | Small Cap Growth
Based in CanadaCompany profile

InMed Pharmaceuticals Inc. is a pre-clinical-stage biopharmaceutical company. The Company specializes in the research and development of cannabinoid-based therapies combined with drug delivery systems. The Company operates through the segment of research and development of pharmaceutical cannabis based-therapies. The Company is working on two products, which include INM-750, for the treatment of Epidermolysis Bullosa (EB), and INM-085, for the treatment of Glaucoma. The INM-750 is a therapy developed for EB designed specifically to modulate disease activity and to alleviate symptoms. The INM-085 is designed as a dual-action cannabinoid ocular therapy. INM-085 is designed as a topical formulation to be administered directly to the eye. It is working on the development of several cannabinoid-based treatments for multiple diseases, including ocular, dermatology, cancer, inflammation, pain and arthritis disease areas. Its subsidiary is Biogen Sciences Inc. (BSI).

Closing Price
$0.2094
Day's Change
0.0234 (12.58%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.24
Day's Low
0.185
Volume
(Heavy Day)
Volume:
805,287

10-day average volume:
271,100
805,287

UPDATE: This simple stock investing strategy combines value, quality and dividends into a winning formula

10:14 am ET November 9, 2019 (MarketWatch)
Print

By Philip van Doorn, MarketWatch

A venerable index has been outperforming other value strategies in recent years

Value stocks have underperformed growth stocks by a wide margin during the extended bull market.

When this briefly reversed during September, Morningstar did a three-part study of data going back to the 1990s -- another period when growth was riding high and value lagged. Its analysts then narrowed their focus to the best-performing value strategies of the past three years and came to a fascinating conclusion.

For large-cap stocks, Morningstar found that tracking the Dow Jones Industrial Average not only delivered better returns than other value strategies over the last three years but it also performed well versus growth strategies for other, longer periods.

Growth's triumph

You may already know that value indexes and the funds that track them have lagged growth indexes and funds since the stock market hit bottom in March 2009, in the wake of the global financial crisis. One big reason is that the value group excludes many of the large technology companies that have increased their sales and earnings exponentially, leading to much better investment returns even though they have traded at much higher ratios to earnings, book value and sales.

Amazon.com (AMZN) is an excellent example -- the internet retail pioneer's shares trade for 66.5 times the consensus earnings-per-share estimate for the next 12 months, based on analysts polled by FactSet. That compares to a forward price-to-earnings ratio of 17.4 for the S&P 500 . Over the past 10 years, Amazon's shares have often traded at much higher forward P/E than they do now. But the stock was up 1,407% for the decade through Nov. 1.

S&P Dow Jones Indices divides the benchmark S&P 500 into value and growth indexes, based on price valuations to earnings, book value and sales. Here's how ETFs that track those two indexes, the full S&P 500 and the Dow have performed over the past 10 years:

It's no surprise that the Vanguard S&P 500 Growth ETF (VOOG) has been the best performer among the four during this strong decade for growth strategies, with the Vanguard S&P 500 Value ETF (VOOV) lagging far behind. But the SPDR Dow Jones Industrial Average ETF (DIA) was only slightly behind the SPDR S&P 500 ETF Trust (SPY). What's remarkable about that is that the Dow represents a value portfolio -- a much more conservative group of companies than the heavily tech-weighted S&P 500.

And now to value

Tom Lauricella and Katherine Lynch of Morningstar pointed out that before the dot-com bubble began to burst in 2000, growth stocks had also outperformed value for years. While that and signs of slowing economic growth might make you think it's a good time to switch to value, the writers cautioned that the current situation is different because "many of the technology stocks that have led the long-running bull market are real companies with real earnings."

That said, what value strategies have been best in recent years? According to Lauricella and Lynch, there has been one main theme: "Value funds that focused on higher-quality companies" tended to perform best, especially those that "focused on dividend-paying companies." They listed the 10 best-performing value-focused mutual funds and exchange traded funds over the past three years, and the winner was the SPDR Dow Jones Industrial Average ETF (DIA).

Let's return to our group of four ETFs shown in the 10-year chart above, now for three years through Nov 1:

Once again, the Vanguard S&P 500 Growth ETF leads, but by less than 1 percentage point over the SPDR Dow Jones Industrial Average ETF.

When considering that it is an index made up of 30 of the best-known U.S. companies, including a lot of slow-growers, many of which feature attractive dividend yields, the Dow's performance has been incredible. And if you now are looking to move more of your money into a more conservative value-oriented, dividend-focused strategy, this is the simplest and the best-performing value index fund among those tracked by Morningstar. And its annual expense ratio is only 0.17%.

The Dow 30

Here are the 30 components of the Dow Jones Industrial Average sorted by three-year total returns (with dividends reinvested) through Nov. 1:

Company Ticker Total return - 3 years Dividend yield Forward price-to-earnings ratio

Boeing Co. US:BA 161% 2.38% 20.2

Microsoft Corp. US:MSFT 154% 1.42% 26.4

Apple Inc. US:AAPL 141% 1.20% 19.8

Visa Inc. Class A US:V 126% 0.66% 28.9

Home Depot Inc. US:HD 112% 2.29% 22.3

JPMorgan Chase & Co. US:JPM 100% 2.82% 12.5

Caterpillar Inc. US:CAT 90% 2.85% 14.0

UnitedHealth Group Inc. US:UNH 89% 1.71% 15.8

American Express Co. US:AXP 88% 1.44% 13.8

McDonald's Corp. US:MCD 86% 2.58% 22.7

Nike Inc. Class B US:NKE 86% 0.99% 29.2

Walmart Inc. US:WMT 82% 1.80% 23.6

Intel Corp. US:INTC 77% 2.23% 12.4

Cisco Systems Inc. US:CSCO 69% 2.98% 14.4

Procter & Gamble Co. US:PG 57% 2.41% 23.8

Merck & Co. Inc. US:MRK 56% 2.59% 16.1

United Technologies Corp. US:UTX 54% 2.00% 17.6

Walt Disney Co. US:DIS 50% 1.33% 24.8

Verizon Communications Inc. US:VZ 45% 4.07% 12.1

Coca-Cola Co. US:KO 41% 2.97% 23.9

Pfizer Inc. US:PFE 38% 3.75% 14.4

Travelers Companies Inc. US:TRV 32% 2.51% 12.4

Goldman Sachs Group Inc. US:GS 28% 2.30% 9.4

Johnson & Johnson US:JNJ 23% 2.90% 14.9

Chevron Corp. US:CVX 23% 4.10% 17.8

3M Co. US:MMM 12% 3.39% 18.6

International Business Machines Corp. US:IBM 1% 4.78% 10.5

Exxon Mobil Corp. US:XOM -6% 5.00% 21.4

Walgreens Boots Alliance Inc. US:WBA -25% 3.19% 10.1

Dow Inc. US:DOW N/A 5.35% 13.8

Source: FactSet

You can click the tickers for more about each company.

To read the Morningstar report in full, see the first section for long-term data that explains periods of outperformance for growth strategies (https://www.morningstar.com/articles/950553/value-investing-a-deep-dive-into-performance). The second section shares insights from value managers (https://www.morningstar.com/articles/950560/value-managers-on-why-the-strategy-has-underperformed), and the third part lists the best-performing value funds (https://www.morningstar.com/articles/950562/what-do-the-top-value-funds-have-in-common) over the past three years.

Create an email alert for Philip van Doorn's Deep Dive columns here (http://www.marketwatch.com/tools/alerts/newsColumn.asp).

-Philip van Doorn; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

November 09, 2019 10:14 ET (15:14 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2019 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2019. All rights reserved.